PD-L1 Monoclonal Antibody

Datasheet
Code CSB-MA878942A1m
Size US$350
Image
  • Western Blot
    Positive WB detected in: A549 whole cell lysate, PC-3 whole cell lysate, HepG2 whole cell lysate, MCF-7 whole cell lysate, 293 whole cell lysate, Hela whole cell lysate
    All lanes: PD-L1 antibody at 1:1000
    Secondary
    Goat polyclonal to Mouse IgG at 1/10000 dilution
    Predicted band size: 34, 21 kDa
    Observed band size: 55, 70 kDa

  • IHC image of CSB-MA878942A1m diluted at 1:100 and staining in paraffin-embedded human tonsil tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

  • IHC image of CSB-MA878942A1m diluted at 1:100 and staining in paraffin-embedded human colon cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

  • Immunofluorescence staining of 293 cells with CSB-MA878942A1m at 1:150, counter-stained with DAPI. The cells were blocked in 10% normal Goat Serum and then incubated with the primary antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Mouse IgG(H+L).

  • Immunofluorescence staining of A549 cells with CSB-MA878942A1m at 1:150, counter-stained with DAPI. The cells were blocked in 10% normal Goat Serum and then incubated with the primary antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Mouse IgG(H+L).

  • Immunofluorescence staining of Hela cells with CSB-MA878942A1m at 1:150, counter-stained with DAPI. The cells were blocked in 10% normal Goat Serum and then incubated with the primary antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Mouse IgG(H+L).

  • Overlay histogram showing 293 cells stained with CSB-MA878942A1m (red line) at 1:300. The cells were incubated in 1x PBS /10% normal goat serum to block non-specific protein-protein interactions followed by primary antibody for 1 h at 4°C. The secondary antibody used was FITC goat anti-mouse IgG(H+L) at 1/200 dilution for 1 h at 4°C. Isotype control antibody (green line) was used under the same conditions. Acquisition of >10,000 events was performed.

  • Overlay histogram showing A549 cells stained with CSB-MA878942A1m (red line) at 1:300. The cells were incubated in 1x PBS /10% normal goat serum to block non-specific protein-protein interactions followed by primary antibody for 1 h at 4°C. The secondary antibody used was FITC goat anti-mouse IgG(H+L) at 1/200 dilution for 1 h at 4°C. Isotype control antibody (green line) was used under the same conditions. Acquisition of >10,000 events was performed.

  • Overlay histogram showing Hela cells stained with CSB-MA878942A1m (red line) at 1:300. The cells were incubated in 1x PBS /10% normal goat serum to block non-specific protein-protein interactions followed by primary antibody for 1 h at 4°C. The secondary antibody used was FITC goat anti-mouse IgG(H+L) at 1/200 dilution for 1 h at 4°C. Isotype control antibody (green line) was used under the same conditions. Acquisition of >10,000 events was performed.

The Latest Promotion Free Antibody trial simple
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No. Q9NZQ7
Alternative Names B7 H antibody; B7 H1 antibody; B7 homolog 1 antibody; B7-H1 antibody; B7H antibody; B7H1 antibody; CD 274 antibody; CD274 antibody; CD274 antigen antibody; CD274 molecule antibody; MGC142294 antibody; MGC142296 antibody; OTTHUMP00000021029 antibody; PD L1 antibody; PD-L1 antibody; PD1L1_HUMAN antibody; PDCD1 ligand 1 antibody; PDCD1L1 antibody; PDCD1LG1 antibody; PDL 1 antibody; PDL1 antibody; Programmed cell death 1 ligand 1 antibody; Programmed death ligand 1 antibody; RGD1566211 antibody
Raised in Mouse
Species Reactivity Human
Immunogen Recombinant Human Programmed cell death 1 ligand 1 protein (19-238AA)
Immunogen Species Homo sapiens (Human)
Conjugate Non-conjugated
Clonality Monoclonal
Isotype IgG2b
Clone No. 14D8C2
Purification Method >95%, Protein G purified
Concentration It differs from different batches. Please contact us to confirm it.
Buffer Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Form Liquid
Tested Applications ELISA, WB, IHC, IF, FC
Recommended Dilution
Application Recommended Dilution
WB 1:1000-1:5000
IHC 1:50-1:200
IF 1:50-1:200
Protocols ELISA Protocol
Western Blotting(WB) Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
Flow Cytometry (FC) Protocol
Troubleshooting and FAQs Antibody FAQs
Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Q&A and Customer Reviews

 Customer Reviews
  • Tested application: WB
    Test sample: Human ovarian cancer
    Primary antibody dilution ratio: 1:1000
    Review: The target band is between 40 and 55. And the antibody strip is in the correct site with high specificity by regular WB operation. It is easy to use .
  • Tested application: WB
    Test sample: Human granulosa cell carcinoma KGN
    Primary antibody dilution ratio: 1:1500
    Review: The antibody strip is correct, but there is a weak band nearby. The technician suggests that experiment steps are to be optimized.

Target Data

Function Involved in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation and cytokine production.
Gene References into Functions
  1. an HBV-pSTAT3-SALL4-miR-200c axis regulates PD-L1 causing T cell exhaustion PMID: 29593314
  2. hypothesized that an oncolytic poxvirus would attract T cells into the tumour, and induce PD-L1 expression in cancer and immune cells, leading to more susceptible targets for anti-PD-L1 immunotherapy PMID: 28345650
  3. multivariate Cox hazards regression analysis identified ALCAM and PD-L1 (both P < 0.01) as potential independent risk factors for primary diffuse pleural mesotheliomas PMID: 28811252
  4. miR-191-5p was identified to have negative correlation with PD-L1 expression and acted as an independent prognostic factor of OS in patients with colon adenocarcinoma. PMID: 30045644
  5. our findings suggest a regulatory mechanism of PD-L1 through data analysis, in vitro and vivo experiments, which is an important factor of immune evasion in GC cells, and CXCL9/10/11-CXCR3 could regulate PD-L1 expression through STAT and PI3K-Akt signaling pathways in GC cells. PMID: 29690901
  6. CD163(+)CD204(+) Tumor-associated macrophages possibly play a key role in the invasion and metastasis of oral squamous cell carcinoma by T-cell regulation via IL-10 and PD-L1 production. PMID: 28496107
  7. Results demonstrated that the expression of PDL1 in colorectal carcinoma tissue was significantly increased compared with the paracancerous tissue. Blocking PDL1 can inhibit tumor growth by activating CD4+ and CD8+ T cells involved in the immune response. PMID: 30272332
  8. miR-574-3p was identified to potentially regulate PD-L1 expression in chordoma, which inversely correlated with PD-L1. Positive PD-L1 expression on tumor cells was associated with advanced stages and TILs infiltration, whereas decreased miR-574-3p level correlated with higher muscle invasion, more severe tumor necrosis and poor patient survival. PMID: 29051990
  9. PD-L1 expression was detected in 69% of cases of primary melanoma of the vulva PMID: 28914674
  10. PD-L1 tumor cell expression is strongly associated with increased HIF-2alpha expression and presence of dense lymphocytic infiltration in clear cell renal cell carcinoma. PMID: 30144808
  11. Different Signaling Pathways in Regulating PD-L1 Expression in EGFR Mutated Lung Adenocarcinoma PMID: 30454551
  12. PD-L1, Ki-67, and p53 staining individually had significant prognostic value for patients with stage II and III colorectal cancer PMID: 28782638
  13. Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma PMID: 30050132
  14. Our results confirm and extend prior studies of PD-L1 and provide new data of PD-L2 expression in lymphomas PMID: 29122656
  15. Positive PD-L1 expression is indicative of worse clinical outcome in Xp11.2 renal cell carcinoma. PMID: 28522811
  16. PD-L1 expression in cancer cells is upregulated in response to DNA double-strand break. PMID: 29170499
  17. Targeting PD-L1 Protein is an efficient anti-cancer immunotherapy strategy. (Review) PMID: 30264678
  18. Suggest that PD-L1 may play a relevant role in metastatic spread and may be a candidate prognostic biomarker in cutaneous squamous cell carcinoma. PMID: 29742559
  19. PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters. PMID: 29874226
  20. SLC18A1 might complement other biomarkers currently under study in relation to programmed cell death protein 1/programmed cell death protein ligand 1 inhibition PMID: 30194079
  21. Low PDL1 expression is associated with mammary and extra-mammary Paget disease. PMID: 29943071
  22. Low PDL1 mRNA expression is associated with non-muscle-invasive bladder cancer. PMID: 29150702
  23. we found that in advanced stage NSCLC patients who received nivolumab, the C allele of PD-L1 rs4143815 and the G allele of rs2282055 were significantly associated with better ORR and PFS. This is the first report that PD-L1 SNP, which was thought to increase PD-L1 expression, is associated with a response to nivolumab. PMID: 28332580
  24. PD-L1 expression differs between the two components of lung ASCs. Given the complexity of lung ASCs, their treatment outcomes may be improved by administration of both EGFR TKIs and anti-PD-1/PD-L1 antibodies in cases where EGFR mutations are present and PD-L1 is overexpressed. PMID: 28387300
  25. IDO and B7-H1 expressions were observed in patients with pancreatic carcinoma tissues and are important markers for PC malignant progression PMID: 30029936
  26. There was higher programmed cell death protein ligand-1(PD-L1) expression in post-treatment EBV DNA-positive patients. Post-treatment positive EBV DNA status maybe a useful biomarker of worse outcomes in early stage -stage extranodal natural killer/T cell lymphoma. PMID: 30116872
  27. PD-L1 is a critical TTP-regulated factor that contributes to inhibiting antitumor immunity. PMID: 29936792
  28. Structural and functional analyses unexpectedly reveal an N-terminal loop outside the IgV domain of PD-1. This loop is not involved in recognition of PD-L1 but dominates binding to nivolumab, whereas N-glycosylation is not involved in binding at all. PMID: 28165004
  29. While mutational analysis appeared similar to that of older patients with OCSCC who lack a smoking history, a comparatively high degree of PD-L1 expression and PD-1/L1 concordance (P=0.001) was found among young female OCSCC patients. PMID: 28969885
  30. PD-L1 expression is predictive of survival in diffuse large B-cell lymphoma, irrespective of rituximab treatment. PMID: 29748856
  31. PD-L1 expression was augmented on CD8+ T cells in BALF of a patient with smoldering adult T-cell lymphoma and Pneumocystis jiroveci pneumonia. This suggested that the PD-1-PD-L1 system may suppress not only antitumor immunity but also host defense against pathogens and thereby allow establishment of chronic HTLV-1 infection and immunodeficiency. PMID: 28967040
  32. MUC1 drives PD-L1 expression in triple-negative breast cancer cells. PMID: 29263152
  33. Positive PD-L1 expression was found in 36.8% of inflammatory breast carcinoma (IBC) samples but was not significantly associated with the clinicopathologic variables examined. Worse overall survival (OS) was significantly associated with positive PD-L1, negative estrogen receptor, and triple-negative status. The 5-year OS rate was 36.4% for patients with PD-L1-positive IBC and 47.3% for those with PD-L1-negative. PMID: 29425258
  34. PD-L1 expression display a highly variable distribution in clear cell renal cell carcinomas and this particularity should be kept in mind when selecting the tumor samples to be tested for immunotherapy. PMID: 29661736
  35. Report relatively low level PD-L1 positivity in treatment-naive acinar prostatic adenocarcinoma. PMID: 30257853
  36. High PD-L1 expression is associated with pulmonary metastases in head and neck squamous cell carcinoma. PMID: 29937180
  37. these data suggest that DNA-damage signaling is insufficient for upregulating PD-L1 in normal human dermal fibroblasts PMID: 29859207
  38. High CD274 expression is associated with Oral Squamous Cell Carcinoma. PMID: 28669079
  39. This study provides important evidence of higher levels of agreement of PD-L1 expression in pulmonary metastasis compared with in multiple primary lung cancer, and high positivity of PD-L1 expression in pulmonary metastatic lesions with wild-type EGFR in an Asian population. PMID: 29254651
  40. High PD-L1 expression is associated with Mycobacterium avium complex-induced lung disease. PMID: 28169347
  41. PD-L1 expression in tumor-associated immune cells may be associated with a higher probability of clinical response to avelumab in metastatic breast cancer PMID: 29063313
  42. The expression of PDL1 was significantly increased following treatment with gefitinib. PMID: 29901173
  43. These results demonstrated that the IFNGinduced immunosuppressive properties of B7H1 in human BM and WJMSCs were mediated by STAT1 signaling, and not by PI3K/RACalpha serine/threonineprotein kinase signaling PMID: 29901104
  44. PD-1/PD-L1 expression is a frequent occurrence in poorly differentiated neuroendocrine carcinomas of the digestive system. PMID: 29037958
  45. High CD274 expression is associated with Epithelial Ovarian Cancer. PMID: 30275195
  46. Studied expression levels of CD274 molecule (PD-L1) in thymic epithelial tumors. Found PD-L1 expression level correlated with the degree of TET malignancy. PMID: 29850538
  47. Authors assessed PD-L1 expression in both tumor cells and tumor-infiltrating immune cells in the tumor specimens (complete histological sections, not tissue microarray). PMID: 28420659
  48. We conclude that a subgroup of advanced disease ovarian cancer patients with high grade tumors, expressing PD-L1, may be prime candidates for immunotherapy targeting PD-1 signaling PMID: 29843813
  49. PD-L1 expression is a prognostic factor related with poor survival among patients that developed non-small cell lung cancer. PMID: 29614306
  50. The inhibition of PTEN also reduced the cancer effects of CD4+ T cells on non-small cell lung cancer (NSCLC) cell lines following miR-142-5p downregulation. Therefore, our study demonstrated that miR-142-5p regulated CD4+ T cells in human NSCLC through PD-L1 expression via the PTEN pathway. PMID: 29767245
  51. Thus, PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma was associated with BIM and VEGFA mRNA expression and with shorter PFS after gefitinib therapy. PMID: 29767258
  52. The expression of PD-L1 in breast-invasive ductal carcinoma was significantly increased, and it was related to histological grading, clinical staging, and lymph node metastasis of breast cancer. PMID: 29516978
  53. Neither IL-17 nor IL-22, cytokines essential in the immunopathogenesis of psoriasis, alters PD-L1 expression in HaCaT cells. PMID: 27897321
  54. PD-L1 expression and RAS status may be the prognostic indicators for metastatic Colorectal Cancer patients with palliative operation. PMID: 29662888
  55. PD-L1 mRNA can be detected and quantitated in circulating tumor RNA of cancer patients. PMID: 29679564
  56. expression of PD-L1 by lymphoma cells and tumor-associated macrophages mediate the trafficking of tumor-associated macrophages, which may explain the immune-escape process of tumor-associated macrophages. PMID: 29067721
  57. Study indicated that PD-L1 expression is a negative prognostic factor in renal cell carcinoma (RCC). The results also indicate PD-L1 expression was associated more aggressive clinical features in patients with RCC. PMID: 29362922
  58. Study in human tumour tissues and cancer cell lines novel interchange between glycosylation and phosphorylation regulating ubiquitination and degradation of PD-L1. This regulatory event is critical for basal-like breast cancer cells that escape immune surveillance via PD-L1/PD-1 interaction. PMID: 27572267
  59. High CD274 expression is associated with non-small cell lung cancer. PMID: 29549910
  60. High CD274 expression is associated with melanoma. PMID: 29286146
  61. the binding affinities of the PD-1-PD-L1/PD-L2 co-inhibitory receptor system, was characterized. PMID: 27447090
  62. High CD274 expression is associated with head and neck squamous cell carcinoma. PMID: 29328389
  63. Twenty-nine percent (n = 2/7) of the PD-L1 positive Poorly differentiated thyroid carcinomas also co-expressed IDO1 PMID: 29372535
  64. Results indicated that three functional polymorphisms of the PD-L1 gene were associated with hepatocellular carcinoma risk and prognosis. PMID: 29940275
  65. this study showed that blood level of PD-L1 increased during pregnancy PMID: 29205636
  66. Findings suggest that patients with programmed cell death 1 ligand 1 (PD-L1) positive tumors may have poor clinical outcomes in malignant salivary gland tumors. PMID: 29409471
  67. PD-1 rs2227982 C>T and PD-L1 rs4143815 C>G polymorphisms increased the risk of ovarian cancer, leading to a poor prognosis, associated with low expressions of PD-1 and PD-L1. PMID: 29171986
  68. It was shown that the expression of CD274, Il-10, and FOXP3 was closely correlated with the clinical characteristics of laryngeal squamous cell carcinoma, including lymph node metastasis and prognosis. PMID: 29257349
  69. High PD-L1 Expression is associated with Malignant Pleural Mesothelioma. PMID: 29079455
  70. MiR-195 regulated immune response of DLBCL through targeting PD-L1. PMID: 29247952
  71. We expected that in vitro PD1/PD-L1 signal that has been optimized in this study will serve as a valuable protocol for preclinical studies involving PD1/PD-L1 pathway. PMID: 29252078
  72. PD-L1-positive tumor cells and M2-type tumor-associated macrophages may contribute to tumor invasion and immune escape at the invasive front. PMID: 29044503
  73. High-PD-L1 expression and low tumor-infiltrating lymphocytes are associated with tumor-infiltrating lymphocytes. PMID: 28488168
  74. High CD274 expression is associated with high grade and more stromal tumor-infiltrating lymphocytes and lymph node metastases of triple negative breast cancer. PMID: 29291717
  75. Radiotherapy could up-regulate the PD-L1 expression through the pathways downstream of EGFR in glioma. PMID: 29396299
  76. High PD-L1 Expression is associated with Lung Adenocarcinoma. PMID: 29127022
  77. Programmed death-1 ligand-1 (PD-L1) rs2890658 A/C single nucleotide polymorphism (SNP) might be used as risk marker of the susceptibility to esophageal squamous cell carcinoma (ESCC) for the Han nationality in a high-incidence population from Northern China. PMID: 29060926
  78. Data suggest that programmed death-ligand 1 (PD-L1) cannot be recommended for the use as a predictive biomarker of BRAF inhibitor (BRAFi)-based therapy in BRAF V600-mutated metastatic melanoma (MM). PMID: 29195116
  79. PD-L1 expression correlates with poorly differentiated medullary cancers in the Lynch-syndrome-associated colorectal cancer in Japanese patients. PMID: 29327160
  80. PD-L1 expression is associated with disease stage and type of EGFR mutation. PD-L1 positivity might be associated with worse RFS among patients with surgically treated EGFR-mutant NSCLC. PMID: 28301925
  81. Data indicate that nuclear H2A histone family, member X protein (gammaH2AX) expression is positively associated with the programmed death-ligand 1 (PD-L1) expression in lung squamous cell carcinoma. PMID: 29275316
  82. Globo H expression was correlated with specific driver mutations in non-small cell lung cancer (NSCLC) tumors, as well as programmed death-ligand 1 (PD-L1). PMID: 29036791
  83. We describe a subset of non-small-cell lung cancer patients who had JAK2 amplifications resulting in high expression of PD-L1 PMID: 28795418
  84. MMP-13 plays a critical role in the shedding/cleavage of PD-L1 in the human head and neck squamous cell carcinoma.The regulation of PD-L1 expression in the tumour micro-environment by matrix metalloproteinases. PMID: 29345283
  85. subset of hereditary non-polyposis colorectal cancer -associated colorectal cancers in this study clearly showed PD-L1 expression of tumor epithelia and immune cells PMID: 29033182
  86. A circulating tumour cell (CTC) PD-L1 assay could be developed as a companion diagnostic tool to potentially predict the efficacy of immune checkpoint blockade treatments PMID: 29224824
  87. Treatment of lung cancer cell lines with a COX2 inhibitor had no impact on PD-L1 expression. PMID: 30061230
  88. summarizes current literature data on the heterogeneity of PD-L1 expression and the relationship with such factors and with clinicopathological features of non-small cell lung cancer.[review] PMID: 29970498
  89. Alteration of the PD-1/PD-L1 pathway can modulate Treg/Th17 balance in asthmatic children. PMID: 29874664
  90. the expression of PD-L1 in both tumor cells and microenvironment is associated with the non-GCB-subtype DLBCL. PMID: 29246182
  91. High expression of PD-L1 is associated with pulmonary metastasis in colorectal cancer. PMID: 29663398
  92. This study shows a significant overexpression of CTLA-4 in >50% of breast carcinomas with no such overexpression of CTLA-4 in benign breast tissues. PDL-1 staining is seen in only a small number of invasive ductal carcinomas (4.1%). PMID: 29672601
  93. These data suggest that the expression of immunosuppressive molecules, including PD-1 ligands and IDO1, by macrophage/microglia may be involved in immune evasion of lymphoma cells. PMID: 29998979
  94. MiR-424 regulates the PD-L1/PD-1 and CD80/CTLA-4 pathways in chemoresistant ovarian cancer. PMID: 27147225
  95. High PDL1 expression is associated with the increase in the ability of surviving breast cancer cells to evade innate and adaptive immunity. PMID: 29367423
  96. High expression of CD274 is associated with pleomorphic carcinoma of the lung. PMID: 29601633
  97. anti-CTLA4/anti-PD-1/PD-L1 combinations versus anti-PD-1/PD-L1 monotherapy was selected as a factor independent of TMB for predicting better RR (77% vs. 21%; P = 0.004) and PFS (P = 0.024). Higher TMB predicts favorable outcome to PD-1/PD-L1 blockade across diverse tumors. PMID: 28835386
  98. PD-L1 immunohistochemistry requires considerable expertise and specific training of pathologists. PD-L1 immunohistochemistry (IHC)can be a companion or complementary diagnostic test depending on the clone employed, the molecular therapy prescribed and the indication of use. PMID: 29069958
  99. results indicate that lung cancer cell lines with EGFR mutations (parental cells) do not harbor high PD-L1 protein expression. In addition, EGFR phosphorylation affects PD-L1 expression after acquisition of resistance to EGFR-TKIs. PMID: 29119113
  100. The majority of OCs were PD-1-positive in intratumoral lymphocytes regardless of MMR status; while MMR-negative OCs exhibited significantly increased CD3+ and CD8+ tumor-infiltrating lymphocytes, and PD-L1+ intratumoral immune cells compared to MMR-proficient OCs. PMID: 29496294

Show More

Hide All

Subcellular Location Isoform 1: Cell membrane, Single-pass type I membrane protein, SUBCELLULAR LOCATION: Isoform 2: Endomembrane system, Single-pass type I membrane protein
Protein Families Immunoglobulin superfamily, BTN/MOG family
Tissue Specificity Highly expressed in the heart, skeletal muscle, placenta and lung. Weakly expressed in the thymus, spleen, kidney and liver. Expressed on activated T- and B-cells, dendritic cells, keratinocytes and monocytes.
Database Links

HGNC: 17635

OMIM: 605402

KEGG: hsa:29126

STRING: 9606.ENSP00000370989

UniGene: Hs.521989

Most popular with customers

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

Copyright © 2007-2018 www.cusabio.com CUSABIO TECHNOLOGY LLC All Rights Reserved. 鄂ICP备15011166号-1